Danaher Corporation

“There have been a few head fakes there in China as we know, and you got folks like Abbott and Danaher who are telling folks to model incremental headwinds in 2026.”

An analyst notes diagnostics peer Danaher is guiding investors to model incremental China headwinds into 2026.

“I would think Videojet would be a pretty good real-time demand indicator for really just customer confidence and such.”

An analyst cites Danaher's Videojet brand, a direct competitor in marking and coding, as a real-time read on customer demand and confidence to benchmark against Veralto's own results.

“you all know I have covered the Danaher for so many years. So whenever I hear about growth investments done at year end, that’s really read out of the Danaher playbook.”

An analyst notes Veralto's year-end growth investments mirror the playbook of its former parent Danaher, which management confirms given its team's Danaher heritage.

“in the tone of discussions with biotech and pharmaceutical customers since the Pfizer MFN announcement came out”

An analyst cites Pfizer's most-favored-nation pricing announcement as a potential catalyst improving pharma customers' confidence to invest in bioprocessing capacity.

“But if we think about our guidance and you mentioned Sarepta here and Aldebron, you know, our guidance in the market is essentially playing out as we expected, but the Alderon Sarepta revenue we expect to be $30 million for the full year.”

Sarepta's gene therapy faced an FDA suspension/safety concerns this quarter; Danaher's Aldevron unit manufactures for Sarepta but expects only ~$30M full-year revenue exposure with minimal second-half contribution.